MajorTricyclic antidepressants (TCA)×Class III antiarrhythmic, selective IKr blocker
Updated · Methodology
Mechanism
Dofetilide is a class III antiarrhythmic. It blocks the rapid component of the delayed rectifier potassium current (IKr), and QT prolongation depends directly on its plasma concentration (dofetilide label, US Food and Drug Administration, FDA). According to the Spanish amitriptyline summary of product characteristics (SmPC), QT-prolonging drugs may increase the likelihood of ventricular arrhythmias when taken with tricyclic antidepressants. Post-marketing reports with amitriptyline itself describe QT prolongation and arrhythmias (amitriptyline SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). Liver enzymes, mainly CYP2D6 and CYP2C19, metabolise amitriptyline, and CYP3A4, CYP1A2 and CYP2C9 also take part (AEMPS). Dofetilide does not inhibit cytochrome P450 enzymes (dofetilide FDA label). The documents describe no pharmacokinetic interaction for this pair.
Symptoms
QT prolongation itself causes no symptoms and shows only on an electrocardiogram (ECG). The Medication Guide of the US dofetilide label lists the warning signs of a dangerous arrhythmia: feeling faint, dizziness and a fast heartbeat. It warns that torsade de pointes can lead to death. In people with supraventricular arrhythmias who took dofetilide, torsade de pointes occurred in 0.8%, mostly within the first three days of treatment (dofetilide label, US Food and Drug Administration, FDA). With amitriptyline, QT prolongation on the ECG is a common adverse reaction, arrhythmia is rare and torsade de pointes is very rare (amitriptyline summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). High doses of amitriptyline are likely to cause arrhythmias and severe hypotension, and these can also occur at normal doses in people with pre-existing heart disease (AEMPS).
Management
Avoid the combination. In the heart rhythm disorders for which dofetilide is given, amitriptyline is contraindicated in its own right. The contraindications section of the Spanish amitriptyline summary of product characteristics (SmPC) lists recent myocardial infarction, any degree of heart block, heart rhythm disorders and coronary insufficiency (amitriptyline SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). Dofetilide is used for atrial fibrillation and atrial flutter (dofetilide label, US Food and Drug Administration, FDA). The US dofetilide label does not recommend dofetilide with other drugs that prolong the QT interval and names tricyclic antidepressants among them (FDA). The Spanish amitriptyline SmPC lists QT-prolonging drugs among combinations that are not recommended (AEMPS), and dofetilide prolongs QT according to its own label (FDA). Dofetilide is not in the Spanish medicines register CIMA. Use amitriptyline with caution in significant bradycardia, decompensated heart failure and with QT-prolonging drugs. Electrolyte disturbances (low or high potassium, low magnesium) increase the risk of arrhythmia (AEMPS). If dofetilide is stopped so that a potentially interacting drug can be given, wait at least two days before starting that drug (FDA). No document states how long to wait after stopping amitriptyline before starting dofetilide. The elimination half-life of amitriptyline is about 25 hours (AEMPS). Start or restart dofetilide only in a facility that can calculate creatinine clearance, provide continuous electrocardiogram (ECG) monitoring and perform cardiac resuscitation for at least three days. Dofetilide is contraindicated if the QT or heart-rate-corrected QT interval (QTc) is above 440 ms (500 ms with ventricular conduction abnormalities). Keep potassium in the normal range before and during treatment (FDA).
Your whole list in one report
Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email
Add more drugsMedicine list: everything you take in one place →
Sources
- AEMPS: Ficha técnica: Amitriptilina (nº registro 89862), sección 4.5 (2026)– AEMPS, CIMA, nº registro 89862, revisión 05/2026, sección 4.5
- AEMPS: Ficha técnica: Amitriptilina, Tryptizol 25 mg (nº registro 37130), secciones 4.4 y 4.5 (2025)– AEMPS, CIMA, nº registro 37130, revisión 01/2025, secciones 4.4 y 4.5
- AEMPS: Ficha técnica: Amitriptilina, Tryptizol 25 mg comprimidos recubiertos con película (nº registro 37130), secciones 4.3, 4.4, 4.5 y 4.8 (2025)– AEMPS, CIMA, nº registro 37130, revisión 01/2025, secciones 4.3, 4.4, 4.5 y 4.8
- FDA: TIKOSYN (dofetilide) capsules prescribing information (2026)– FDA, DailyMed setid 02438044-d6a3-49e9-a1ac-3aad21ef2c8c (Pfizer), revisión 04/2026 (versión 30), Boxed Warning, Contraindications, Warnings (Ventricular Arrhythmia, Use with Drugs that Prolong QT Interval and Antiarrhythmic Agents), Precautions (Drug-Drug Interactions), Dosage and Administration